

## References

S-224

1. National Comprehensive Cancer Network (NCCN). Waldenströms Macroglobulinemia/Lymphoplasmacytic Lymphoma. Version 1.2014.
2. Dimopoulos M, Kastiris E, Owen R, et al. Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: International Workshops on WM(IWWM)-7 consensus. *Blood*. 2014; 124(9):1404-1411.
3. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Waldenströms Macroglobulinemia/Lymphoplasmacytic Lymphoma. Version 1.2017.
4. Treon S. How I treat Waldenstrom macroglobulinemia. *Blood Journal*. 2015; 126(6): 721-732.
5. American Cancer Society. Stem cell transplant for Waldenström macroglobulinemia. 2015.
6. Castillo J, Ghobrial I, Treon S. Biology, prognosis, and therapy of Waldenström macroglobulinemia. *Cancer Treatment and Research*. 2015: 165:177-195.
7. Cornell R. Allogeneic transplantation for relapsed waldenström macroglobulinemia and lymphoplasmacytic lymphoma. *Biology of Blood and Marrow Transplantation*. 2017;23: 60-66.
8. Leblond V. Treatment recommendations from the Eighth International Workshop on Waldenstrom's Macroglobulinemia. *Blood*. 2016;128(10): 1321-1328.
9. Abeykoon J. New developments in the management of Waldenström macroglobulinemia. *Cancer Management and Research*. 2017;9: 73-83.
10. Kapoor P, Ansell SM, Fonseca R, et al. Diagnosis and management of Waldenstrom macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. *JAMA Oncol*. Sep 1 2017;3(9):1257-1265
11. Talaulikar D, Tam CS, Joshua D, et al. Treatment of patients with Waldenstrom macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. *Intern Med J*. Jan 2017;47(1):35-49.